Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P23771
UPID:
GATA3_HUMAN
Alternative names:
GATA-binding factor 3
Alternative UPACC:
P23771; Q5VWG7; Q5VWG8; Q96J16
Background:
Trans-acting T-cell-specific transcription factor GATA-3, also known as GATA-binding factor 3, plays a pivotal role in immune responses. It acts as a transcriptional activator, binding to the enhancer of the T-cell receptor alpha and delta genes, and is essential for the T-helper 2 (Th2) differentiation process. GATA-3 is also involved in macrophage transcriptional activation and metabolic reprogramming in response to IL33, facilitating the differentiation of inflammation-resolving macrophages upon tissue injury.
Therapeutic significance:
GATA-3 is linked to Hypoparathyroidism, sensorineural deafness, and renal disease, a condition characterized by steroid-resistant nephrosis with progressive renal failure. Understanding the role of GATA-3 could open doors to potential therapeutic strategies for this multifaceted disease.